February 18, 2010 (FinancialWire) — Phase Forward Inc. (NASDAQ: PFWD), a provider of data management solutions for clinical trials and drug safety, said that its board of directors has authorized the repurchase of an additional $25 million of its common stock, to be completed by December 31, 2010.

The latest authorization follows the completion of the company’s previous $40.0 million share repurchase program. The company said it expects to use cash on hand and cash generated from future operations to fund repurchases of its common stock.

Massachusetts-based Phase Forward said its products and services have been utilized in over 10,000 clinical trials involving more than one million clinical trial study participants at over 300 organizations and regulatory agencies worldwide.

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.